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1638Cord-Blood Hematopoietic Stem Cell
Transplant Confers an Increased Risk for Human
Herpesvirus-6-Associated Acute Limbic Encephalitis:
A Cohort Analysis
Joshua A. Hill,1 Sophia Koo,2 Belisa B. Guzman Suarez,2 Vincent T. Ho,3
Corey Cutler,3 John Koreth,3 Philippe Armand,3 Edwin P. Alyea III,3 Lindsey R. Baden,2
Joseph H. Antin,3 Robert J. Soiffer,3 Francisco M. Marty2Human herpesvirus-6 (HHV-6) frequently reactivates after allogeneic hematopoietic stem cell transplanta-
tion (HSCT); its most severe manifestation is the syndrome of posttransplantation acute limbic encephalitis
(HHV-6-PALE). The epidemiology, risk factors, and characteristics of HHV-6-PALE after unrelated cord-
blood transplantation (UCBT) are not well characterized. We analyzed 1344 patients undergoing allogeneic
HSCT between March 2003 and March 2010 to identify risk factors and characteristics of HHV-6-PALE. The
cohort included 1243 adult-donor HSCTand 101 UCBTrecipients. All patients diagnosed with HHV-6-PALE
had HHV-6DNA in cerebrospinal fluid (CSF) specimens in addition to symptoms and studies indicating limbic
encephalitis. Nineteen cases (1.4%) of HHV-6-PALE were identified during this study: 10 after UCBT (9.9%)
and 9 after adult-donor HSCT (0.7%), for an incidence rate of 1.2 cases/1000 patient-days compared to 0.08
cases/1000 patient-days (P \ .001), respectively. Risk factors for HHV-6-PALE on multivariable Cox
modeling were UCBT (adjusted hazard ratio [aHR], 20.0; 95% confidence interval [CI], 7.3-55.0; P \
.001), time-dependent acute graft-versus-host disease (aGVHD) grades II to IV (aHR, 7.5; 95% CI,
2.8-19.8; P \ .001), and adult-mismatched donor (aHR, 4.3; 95% CI, 1.1-17.3; P 5 .04). Death from
HHV-6-PALE occurred in 50% of affected patients undergoing UCBTand no recipients of adult-donor cells.
Patients receiving UCBT have increased risk for HHV-6-PALE and greater morbidity from this disease.
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Human herpesvirus-6 (HHV-6) is an opportunis-
tic pathogen in patients undergoing allogeneic hema-
topoietic stem cell transplantation (HSCT). Primary
infection with this herpesvirus typically occurs during
infancy [1]. After acute infection, HHV-6 is able to es-1Department of Medicine, Brigham andWomen’s Hospi-
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6/j.bbmt.2012.04.016tablish latency in a wide variety of host cells, although
it replicates most efficiently in vitro in CD41 T lym-
phocytes [2]. There are 2 closely related variants of
HHV-6, types A and B; HHV-6B is the more frequent
cause of human disease. Antibodies to either or both
variants are found in .95% of adults [2-5]. HHV-6
DNA becomes detectable in plasma samples from ap-
proximately 40% to 50% of patients undergoing
HSCT from adult donors and up to 80%of patients af-
ter unrelated umbilical cord blood HSCT (UCBT)
within 6 weeks after transplantation, a phenomenon
attributed most commonly to HHV-6 reactivation
[6-11]. The HHV-6B variant accounts for approxi-
mately 98% of these events [12-14]. HHV-6 reactiva-
tion after HSCT has been associated with many
complications including delayed engraftment, graft re-
jection, grade II to IV acute graft-versus-host disease
(aGVHD), central nervous system (CNS) disease,
and increased all-cause mortality [9,11,15-24].
One of the most debilitating and sometimes fatal
consequences of HHV-6 reactivation after HSCT is
the syndrome of posttransplantation acute limbic
Biol Blood Marrow Transplant 18:1638-1648, 2012 1639HHV-6 Encephalitis after Unrelated Cord-Blood HSCTencephalitis (HHV-6-PALE) [9,19-24]. Risk factors
for this disease are poorly understood and variably
reported as younger age, mismatched or unrelated
donor (URD), sex mismatched donor, underlying
malignancy other than hematologic malignancy in
first remission or chronic myelogenous leukemia
chronic phase, low pre transplantation anti-HHV-6
IgG titer, treatment with anti-T cell monoclonal anti-
bodies or steroids, high-level plasma HHV-6 viremia,
and aGVHD grades II to IV [7-10,15,23,25-27].
HHV-6-PALE after HSCT is well described
[9,19-24]. Several case reports and series of HHV-6-
PALE after UCBT have been published [21,28-30],
but the epidemiology, risk factors, and characteristics
of this syndrome in patients receiving UCBT are not
well characterized. Given the increased incidence of
HHV-6 reactivation and higher plasma viral loads in
recipients of UCB [6,7], these patients may be at risk
for more frequent and severe manifestations of CNS
disease. This study describes the epidemiology, risk
factors, and characteristics of HHV-6-PALE in pa-
tients undergoing UCBT at our institution.PATIENTS AND METHODS
Patients
All patients who underwent an initial allogeneic
HSCT between March 2003 and March 2010 were
identified through the clinical database at Dana-
Farber Cancer Institute/Brigham and Women’s
Hospital (DFCI/BWH) Hematopoietic Stem Cell
Transplantation Program. This period was chosen to
correspond with the introduction of UCBT at our in-
stitution and the availability of a standardized HHV-6
cerebrospinal fluid (CSF) PCR assay for testing all
samples at a single reference laboratory. A waiver of
the requirement for informed consent was granted by
the Office for Human Research Studies of Dana-
Farber/Harvard Cancer Center.
A total of 1367 patients underwent allogeneic
HSCT during the study period. Twenty-three patients
were excluded due to receiving an initial allogeneic
HSCT before the start of the study period or during
the study period at an outside institution. A final co-
hort of 1344 patients undergoing initial allogeneic
HSCT during the study period was used for this anal-
ysis: 725 were from adult URDs (633HLA-matched at
6/6 loci, 92 HLA-mismatched), 518 from adult related
donors (508 HLA-matched, 10 HLA-mismatched),
and 101 from mismatched UCB donors (Tables 1
and 2). Fifteen patients underwent a second HSCT
procedure during the 100-day follow-up period from
the date of the initial HSCT. In this group, 8 patients
had 2 UCBTs, 6 patients had 2 HSCTs from adult do-
nors, and 1 patient had an adult-donor HSCT fol-
lowed by UCBT. Neither foscarnet nor ganciclovirwere used for antiviral prophylaxis during this study
period. Patients received preemptive therapy for cyto-
megalovirus (CMV) DNAemia primarily with ganci-
clovir or valganciclovir, based on a CMV hybrid
capture assay (Digene, Gaithersburg, MD) or a real-
time PCR assay (Qiagen, Germantown, MD).
Covariates and Definitions
Data on covariates of interest (Tables 1 and 2) were
identified through the DFCI/BWH HSCT database,
the Partners Healthcare System Research Patient
Data Repository, and review of the electronic and pa-
per medical records. Engraftment day was defined as
the first of 3 consecutive days of an absolute neutrophil
count greater than .500 cells/mL. Incidents of
aGVHD were defined according to the consensus cri-
teria [31], and data were collected for day of onset,
maximum overall grade, and drugs used for treatment.
Conditioning regimens were grouped as myeloa-
blative or reduced-intensity conditioning (RIC). Mye-
loablative conditioning consisted of different
combinations of chemotherapeutic agents, but a ma-
jority included cyclophosphamide and 1400 cGy total
body irradiation (TBI) delivered in 7 fractions [32]. A
minority received high-dose busulfan and cyclophos-
phamide. RIC primarily consisted of fludarabine
with low-dose busulfan or fludarabine with melphalan,
combined with rabbit anti-thymocyte globulin (ATG;
at a dose of 6 mg per kilogram of body weight) [33].
ATG use was primarily restricted to RIC UCBT and
a few cases of RIC adult-donor HSCT [34,35].
Prophylaxis for GVHD in patients undergoing adult-
donor HSCT consisted of tacrolimus with methotrex-
ate and/or sirolimus in a majority of cases, as well as
cyclosporine with mycophenolate mofetil [32]. In
UCBT, GVHD prophylaxis consisted primarily of ta-
crolimus with sirolimus or cyclosporine with myco-
phenolate mofetil [34-36]. Patients participated in
single-arm or randomized protocols or were treated
with conditioning and aGVHD prophylaxis regimens
at the discretion of the treating physicians.
HHV-6-PALE was diagnosed in patients who had
detectable HHV-6DNA in their CSF in the context of
acute-onset altered mental status, amnesia, seizures, or
other evidence of medial temporal lobe disease involv-
ing the limbic system and no other identifiable etiology
after extensive workup [19]. Cases were reviewed in
detail for day of HHV-6-PALE symptom onset, CSF
results, electroencephalogram (EEG) and magnetic
resonance imaging (MRI) findings, antiviral and anti-
convulsant treatments, concomitant clinical and labo-
ratory findings, and patient outcomes.
HHV-6 Testing
Prospective and routine monitoring of plasma
HHV-6 DNA by PCR after HSCTwas not performed
in this patient cohort. Testing was performed at the
1640 Biol Blood Marrow Transplant 18:1638-1648, 2012J. A. Hill et al.discretion of the treating clinicians, often in the setting
of fever workup, altered mental status, or other con-
ditions raising suspicion for HHV-6 reactivation.
However, CSFHHV-6 PCR testing was routinely per-
formedon allCSF specimens obtained frompatients af-
ter HSCT during the study period, and all patients
suspectedofhavingHHV-6-PALEunderwenta lumbar
puncture. Testing for HHV-6 DNA was performed at
Associated Regional and University Pathologists (Salt
Lake City, UT) using a PCR assay with a quantitative
range between 1000 and 999 106 copies/mL. Detect-
able HHV-6DNA at levels\1000 or.999 106 cop-
ies/mL is reported as such. The same assay was used for
all CSF specimens in this study, which distinguishes be-
tween HHV-6A and B variants. Associated Regional
and University Pathologists personnel were unaware
of the patient conditions prompting HHV-6 testing.
Specific analysis for chromosomally integrated HHV-
6 (ciHHV-6) was not performed.
Statistical Analysis
Person time-at-riskwas censored at day ofHHV-6-
PALE symptom onset, death, or 100 days after time of
transplantation. Censoring after 100 days was chosen
given the occurrence of HHV-6-PALE during this pe-
riod in most reported cases [9,19-24] and peak plasma
HHV-6 reactivation 3 to 4 weeks after HSCT [7,8].
In addition, no cases of HHV-6-PALE have been
diagnosed at our institution beyond 100 days after
transplantation. Baseline patient characteristics were
compared using the 2-sided Fisher exact test, chi-
square test, or Wilcoxon rank sum test as appropriate.
HHV-6-PALE incidence rates (IRs), incidence rate ra-
tios (IRRs), and their 95% confidence intervals (CIs)
were calculatedwith theTaylor series andByarmethod,
respectively, using OpenEpi version 2.3.1 (http://
www.openepi.com; Atlanta, GA). Kaplan-Meier curves
were generated for time-to-event analyses.
Characteristics associated with HHV-6-PALE
were analyzed with Cox modeling and aGVHD was
modeled as a time-varying covariate. Mismatched
and URD variables were only compared in the adult
donor cohort to avoid overestimating their association
with HHV-6-PALE by including patients who under-
wentUCBT, who receivedmismatched andURDcells
in all cases. We explored the potential diagnostic value
of HHV-6 plasma DNA levels for HHV-6-PALE by
generating receiver-operating characteristic (ROC)
curves. P values\ .05 were considered statistically sig-
nificant. SAS version 9.2 (SAS Institute, Cary, NC)was
used for these analyses.
RESULTS
HHV-6-PALE Incidence and Risk Factors
HHV-6-PALE was diagnosed in 19 of 1344 pa-
tients who underwent HSCT during the study period.The baseline characteristics of the cohort, along with
stratified IRs and crude IRRs according toHSCTbase-
line covariates, are presented in Table 2. There were
125,288 patient-days of observation, and no patients
were lost to follow-up before 100 days after transplanta-
tion. The cumulative incidence of HHV-6-PALE was
1.4% for an overall IR of 0.15 of 1000 patient-days
(95%CI, 0.09-0.24).TheHHV-6-PALEIRwashigher
among patients who underwent UCBT (10 of 101; IR,
1.2 of 1000 patient-days) compared with adult-donor
HSCT recipients (9 of 1243; IR, 0.08 of 1000 patient-
days; IRR, 15.5; P\ .001; Table 2). Two of the cases
occurred among 8 patients who underwent a second
UCBTwithin100days; no casesoccurred after a second
adult-donor HSCT. Additional characteristics associ-
atedwithHHV-6-PALEonunivariable analysis are de-
tailed inTable 2.Many of these variables were collinear
with UCBT (Table 1). Although patient-level antiviral
treatment for CMVDNAemia was not captured, there
was no association betweenCMVrecipient seropositiv-
ity and HHV-6-PALE.
Univariable and multivariable hazard ratios (HRs)
were calculated for possible risk factors as shown in
Table 3. Significant covariates on univariable analyses
and other covariates of interest were evaluated in mul-
tivariable models, accounting for the absolute number
of events. These multivariable models maintained sta-
ble adjustedHRs (aHRs) with up to 3 variables, despite
the low event rate of HHV-6-PALE. In the final mul-
tivariable Cox model, UCBT (aHR, 20.0; 95% CI,
7.3-55.0; P \ .001), time-dependent aGVHD
grades II to IV (aHR, 7.5; 95% CI, 2.8-19.8; P \
.001), and adult mismatched donor (aHR 4.3; 95%
CI, 1.1-17.3; P 5 .04) remained predictive of HHV-
6-PALE. To check the robustness of the data without
including the 2 cases after a second UCBT, the same
cohort was restricted to patients only receiving 1
HSCT with additional censoring at the day of the sec-
ond HSCT. The findings and estimates of risk were
similar (data not shown).Clinical Features of HHV-6-PALE
All patients were infected with the HHV-6B vari-
ant. Comparison of the 19 patients who developed
HHV-6-PALE revealed interesting differences. Ten
of the cases occurred afterUCBT, and9 of the cases fol-
lowed adult-donor HSCT: 6 were from matched-
URDs; 3 from mismatched-URDs; and 1 from
amatched-related donor. Four patients never engrafted
after their UCBT, whereas all adult-donor HSCT re-
cipients engrafted. In thosewho engrafted, engraftment
occurred at a median of 24 days (range, 16-59 days) in
the UCBT cohort and 12 days (range, 4-14 days) in
the adult-donor group. Encephalitis developed before
engraftment in 7 recipients of UCB compared with
1 recipient of adult-donor cells. HHV-6-PALE
Table 1. Characteristics of Allogeneic HSCT Cohort According to Stem Cell Source (DFCI/BWH March 2003-March 2010)
Characteristics UCBT (%)* Adult-donor HSCT (%) P Value
No. of patients 101 1243 NA
Median age, years (IQR, range) 48 (37-58, 19-67) 51 (41-58, 18-74) .10
Male sex 54 (53.4) 721 (58) .37
Race .002
Nonwhite 11 (10.9) 43 (3.5)
White 90 (89.1) 1200 (96.5)
Primary disease .06
AML 34 (33.7) 456 (36.7)
NHL 23 (22.8) 187 (15.0)
MDS 10 (9.9) 146 (11.8)
ALL 7 (6.9) 106 (8.5)
CLL 5 (5.0) 102 (8.2)
CML 5 (5.0) 82 (6.6)
HD 8 (7.9) 54 (4.3)
AA 7 (6.9) 38 (3.1)
MM 0 41 (3.3)
MPD 2 (2.0) 31 (2.5)
Conditioning regimen <.001
Reduced-intensity 76 (75.3) 639 (51.4)
Myeloablative 25 (24.8) 604 (48.6)
HLA match† <.001
Mismatched donor 101 (100) 102 (8.2)
Matched donor 0 (0) 1141 (91.8)
Donor relatedness <.001
URD 101 (100) 725 (58.3)
Related donor 0 518 (41.7)
Conditioning agents‡
Fludarabine 92 (91.1) 620 (49.9) <.001
I.V. busulfan 3 (4.0) 650 (52.3) <.001
Cyclophosphamide 30 (29.7) 609 (49.0) <.001
TBI 30 (29.7) 544 (43.8) .006
ATG 69 (68.3) 81 (6.5) <.001
Melphalan 67 (66.3) 8 (0.6) <.001
Thiotepa 0 17 (1.4) 1
Etoposide 0 6 (0.5) 1
BCNU 0 6 (0.5) 1
CMV recipient seropositivity§ .03
CMV seropositive 41 (40.6) 592 (47.9)
CMV seronegative 60 (59.4) 644 (52.1)
aGVHDk .19
Grades II-IV 17 (16.8) 279 (22.5)
None-grade I 84 (83.2) 964 (77.6)
Subsequent transplantation before 100 days¶ <.001
Yes 8 (7.9) 7 (0.6)
No 93 (92.1) 1236 (99.4)
HSCT indicates hematopoietic stem cell transplantation; DFCI/BWH, Dana-Farber Cancer Institute/Brigham and Women’s Hospital; UCBT, unrelated
cord blood transplantation; NA, not applicable; IQR, interquartile range; AML, acute myelogenous leukemia; NHL, non-Hodgkin lymphoma; MDS, mye-
lodysplastic syndrome; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HD, Hodgkin’s dis-
ease; AA, aplastic anemia; MM, multiple myeloma; MPD, myeloproliferative disease; TBI, total body irradiation; ATG, rabbit antithymocyte globulin;
BCNU, carmustine; CMV, cytomegalovirus; aGVHD, acute graft-versus-host disease.
*Percentages in parenthesis refer to the total number of patients in each column. Total numbers are the same as in Table 1.
†Patients were considered HLA-matched if all 6/6 HLA A, B, and DR were identical.
‡Conditioning agents were used in a variety of combinations across the cohort. Because the agents are not mutually exclusive variables and patients
received more than one, P value calculations are binary for the agent and human herpesvirus-6-posttransplantation acute limbic encephalitis (HHV-
6-PALE).
§Seven adult-donor HSCTrecipients had unknown CMV serostatus.
kPatients were censored if aGVHD occurred after HHV-6-PALE onset.
¶Subsequent transplants in UCB recipients were all UCBT. Subsequent transplantations in adult-donor HSCTrecipients were 6 peripheral blood HSCTs
and 1 UCBT.
Biol Blood Marrow Transplant 18:1638-1648, 2012 1641HHV-6 Encephalitis after Unrelated Cord-Blood HSCTsymptom onset occurred at a median of 32 days (range,
16-67 days) in patients who underwent UCBT com-
pared with 20 days (range, 7-37 days) in patients who
underwent adult-donor HSCT (P 5 .07).
The manifestations of HHV-6-PALE demon-
strated previously were consistent with those observed
in this study [19]. Most patients had a similar array ofsymptoms notable for altered mental status, antero-
grade amnesia with marked deficit in short-termmem-
ory recall (but not registration), and intermittent
agitation superimposed on lethargy. Neurologic ex-
aminations were otherwise unrevealing. Symptoms
were acute in onset with waxing and waning courses.
Visual hallucinations developed in 3 UCBT recipients
Table 2. Characteristics of Allogeneic HSCT Cohort, Cases of HHV-6-PALE, and Crude IRs and IRRs within 100 Days of Trans-
plantation (DFCI/BWH March 2003-March 2010)
Characteristics No. HHV-6-PALE* % P Value Days at Risk† IR (95% CI)‡ IRR (95% CI)§
Cohort 1344 19 1.4 NA 125,288 0.15 (0.09-0.2) NA
Recipient age, quartiles, y .89
18-40 338 6 1.8 31,405 0.19 (0.07-0.4) 1
40-51 339 4 1.2 31,469 0.13 (0.03-0.3) 0.67 (0.2-2.4)
51-58 330 5 1.5 30,793 0.16 (0.05-0.4) 0.85 (0.3-2.8)
58-74 337 4 1.2 31,621 0.13 (0.03-0.3) 0.66 (0.2-2.3)
Recipient race .04
Nonwhite 54 3 5.6 4964 0.60 (0.1-1.8) 4.55 (1.3-15.6)
White 1290 16 1.2 120,324 0.13 (0.08-0.2) NA
Primary disease .95
AML 490 5 1.0 45,282 0.11 (0.04-0.3) 1
NHL 210 4 1.9 19,823 0.20 (0.05-0.5) 1.83 (0.5-6.8)
MDS 156 3 1.9 14,331 0.21 (0.04-0.6) 1.90 (0.5-7.9)
ALL 113 2 1.8 10,476 0.19 (0.002-0.7) 1.73 (0.3-8.9)
CLL 107 2 1.9 10,204 0.20 (0.02-0.7) 1.78 (0.3-9.1)
CML 87 1 1.2 8037 0.12 (0.002-0.7) 1.13 (0.1-9.6)
HD 62 1 1.6 5915 0.17 (0.002-0.9) 1.53 (0.2-13.1)
AA 45 0 0 4137 NA NA
MM 41 0 0 3945 NA NA
MPD 33 1 3.0 3138 0.32 (0.004-1.8) 2.89 (0.3-24.7)
Conditioning regimen .33
Myeloablative 629 11 1.8 57,353 0.19 (0.1-0.3) 1.63 (0.7-4.05)
Reduced-intensity 715 8 1.1 67,935 0.12 (0.05-0.2) NA
Stem cell source <.001
UCBT 101 10 9.9 8406 1.20 (0.6-2.2) 15.5 (6.3-38.0)
Adult-donor HSCT 1243 9 0.7 116,882 0.08 (0.04-0.2) NA
HLA match, adult cellsk .03
Mismatched donor 102 3 2.9 9070 0.33 (0.07-1.0) 5.94 (1.5-23.8)
Matched donor 1141 6 0.5 107,812 0.06 (0.02-0.1) NA
Donor relatedness, adult cellsk .09
URD 725 8 1.1 67,601 0.12 (0.05-0.2) 5.83 (0.7-46.6)
Related donor 518 1 0.2 49,281 0.02 (0.0003-0.1) NA
Conditioning agents
Fludarabine 712 10 1.4 .98 67,132 0.15 (0.07-0.3) 1
I.V. busulfan 653 2 0.3 <.001 62,726 0.03 (0.004-0.1) 0.21 (0.05-1.0)
Cyclophosphamide 639 11 1.7 .36 58,169 0.19 (0.09-0.3) 1.27 (0.5-3.0)
TBI 574 11 1.9 .18 52,079 0.21 (0.1-0.4) 1.42 (0.6-3.3)
ATG 150 7 4.7 .003 13,852 0.51 (0.2-1.04) 3.39 (1.3-8.9)
Melphalan 75 6 8.0 <.001 6340 0.95 (0.4-2.06) 6.35 (2.3-17.5)
Thiotepa 17 0 0 1 1660 NA NA
Etoposide 6 0 0 1 600 NA NA
BCNU 6 0 0 1 600 NA NA
CMV recipient seropositivity .82
CMV seropositive 652 10 1.5 60,742 1.65 (0.79-3.03) 1.17 (0.47-2.89)
CMV seronegative 685 9 1.3 64,091 1.40 (0.64-2.67) NA
aGVHD .05
Grades II-IV 296 8 2.7 27,039 0.30 (0.1-0.6) 2.64 (1.06-6.6)
None-grade I 1048 11 1.1 98,249 0.11 (0.06-0.2) NA
HSCT indicates hematopoietic stem cell transplantation; HHV-6-PALE, human herpesvirus-6-posttransplantation acute limbic encephalitis; IRs, inci-
dence rates; IRRs, incidence rate ratios; DFCI/BWH, Dana-Farber Cancer Institute/Brigham and Women’s Hospital; CI, confidence interval; NA, not
applicable; AML, acute myelogenous leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; ALL, acute lymphocytic leukemia;
CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HD, Hodgkin’s disease; AA, aplastic anemia; MM, multiple myeloma; MPD,
myeloproliferative disease; UCBT, unrelated cord blood transplantation; URD, unrelated donor; TBI, total body irradiation; ATG, rabbit antithymocyte
globulin; BCNU, carmustine; CMV, cytomegalovirus; aGVHD, acute graft-versus-host disease.
*HHV-6-PALE was defined as a positive cerebrospinal fluid (CSF) PCR for HHV-6 DNA in addition to characteristic clinical findings within 100 days of
transplantation.
†Days at risk were censored at day of HHV-6-PALE symptom onset, death, or 100 days after transplantation.
‡IR indicates crude incidence rate of cases per 1000 patient-days after HSCT. IR and CI were calculated using the Taylor series.
§IRR indicates crude incidence rate ratio when compared with other levels of the covariate. IRR and CI were calculated using the Byar method.
kOnly patients undergoing adult-donor HSCTare included given that all patients undergoing UCBTreceived mismatched-unrelated cells.
1642 Biol Blood Marrow Transplant 18:1638-1648, 2012J. A. Hill et al.but were not seen in adult-donor recipients. Concom-
itant conditions documented in a few patients from
both groups included the syndrome of inappropriate
antidiuretic hormone secretion and autonomic insta-
bility with labile blood pressures or hypothermia.MRI findings were significant for T2 hyperintense
lesions on fluid attenuation inversion recovery se-
quences of the medial temporal lobe in a limbic neuro-
anatomic distribution in 12 of 17 patients, primarily
affecting the hippocampus, uncus, and amygdala
Table 3. Proportional Hazards Modeling of Risk of HHV-6-PALE after Allogeneic HSCT
Characteristics Univariable HR (95% CI) P Value Multivariable HR (95% CI)* P Value
UCBT 14.5 (5.9-35.8) <.0001 20.0 (7.3-55.0) <.0001
Male 1.61 (0.6-4.2) .34 NA NA
Nonwhite 4.63 (1.4-15.9) .01 NA NA
Myeloablative conditioning 1.60 (0.6-4.0) .31 NA NA
Mismatched adult donor† 2.38 (0.7-8.2) .17 4.3 (1.1-17.3) .04
Unrelated adult donor 0.62 (0.3-1.5) .30 NA NA
ATG 4.68 (1.8-11.9) .001 NA NA
Acute GVHD: grades II-IV‡ 8.07 (3.08-21.2) <.0001 7.5 (2.8-19.8) <.0001
HHV-6-PALE indicates human herpesvirus-6-posttransplantation acute limbic encephalitis; HSCT, hematopoietic stem cell transplantation; HR, hazard
ratio; CI, confidence interval; UCBT, unrelated cord blood transplantation; NA, not applicable; ATG, rabbit antithymocyte globulin; aGVHD, acute graft-
versus-host disease.
*Multivariable Cox model analysis adjusting for UCBT, time-dependent aGVHD grades II to IV, and mismatched donor.
†To accurately calculate values for mismatched and unrelated donors (URDs), a dummy variable was made to separate the analysis into 3 groups (adult-
donor HSCTmismatched or unrelated versus UCBT versus matched or unrelated HSCT) to avoid counting patients who underwent UCBT twice, given
that all UCBTwere mismatched-URDs in this cohort.
‡Acute GVHD was modeled as a time-varying covariate.
Biol Blood Marrow Transplant 18:1638-1648, 2012 1643HHV-6 Encephalitis after Unrelated Cord-Blood HSCT(Figure 1). One recipient of UCB had extensive extra-
limbic abnormalities. Two patients did not have brain
MRIs.
EEGs obtained in 16 of 19 patients had similar
findings, primarily revealing varying degrees of bilat-
eral theta and delta slowing consistent with mild to
severe encephalopathy. Among recipients of an
adult-donor HSCT, 8 of 9 were treated with levetira-
cetam for seizures or seizure prophylaxis. Generalized
tonic-clonic seizures were confirmed in 3 of these pa-
tients before starting an anti-epileptic drug. Median
time from symptom onset to treatment with an anti-
epileptic drug in this group was 3 days (range, 0-56
days). In the UCBT cohort, 6 of 10 patients were
treated with levetiracetam for a seizure prophylaxis
median of 5.5 days (range, 2-15 days) after symptom
onset. No documented seizures occurred among
UCBT recipients, although 2 patients demonstrated
periodic epileptiform discharges on EEG.
The first lumbar puncture after symptom onset re-
vealed elevated CSF total protein levels (median, 53
mg/dL; range, 10-133) in most patients from both
groups. Lymphocytic pleocytosis was found in a mi-
nority of patients and was less pronounced in the pa-
tients who underwent UCBT (median 3 cells/mm3;
range, 0-16) than the adult-donor group (median 9
cells/mm3; range, 0-25). Red blood cell and glucose
levels were generally within the expected limits. CSF
HHV-6 viral loads were higher in patients with
HHV-6-PALE after UCBT (median, 3.5  105 cop-
ies/mL; range, 5980 to .106) than adult-donor
HSCT (median, 3740 copies/mL; range, \1000
to .2  105; P 5 .01).Can HHV-6 Plasma Viral Load Predict HHV-6-
PALE?
Of 142 patients who underwent adult-donor HSCT
tested within 100 days of transplantation, 43 (30.3%)
had positive plasma HHV-6 PCR results. Of 68 patientswho underwent UCBT tested within 100 days, 49
(72.1%) had detectable HHV-6 DNA at a median of 22
days (range, 9-69 days). Peak plasma viral loads were
higher afterUCBT(median, 3.4 104 copies/mL; range,
\1000 to.106) than adult-donorHSCT (median, 4.4
103 copies/mL; range, \1000 to .106; P 5 .01). All
patients with HHV-6-PALE who were tested (17 of 19)
had concurrent HHV-6 viremia.
After UCBT, patients who developed HHV-6-
PALE had higher viral loads (median, 3.9  105 cop-
ies/mL; range, 3.1  104 to .106) than those who
did not (median, 1.9  104 copies/mL; range,\1000
to .106; P 5 .001). Peak values were detected
a median of 1 day (range, 217 to 9 days) from HHV-
6-PALE symptom onset, and treatment was started
a median of 3 days (range, 23 to 23 days) from detec-
tion of plasma HHV-6 DNA.
To explore the potential diagnostic performance
of blood HHV-6 viral loads to identify cases of
HHV-6-PALE, ROC curves were constructed to eval-
uate the sensitivity and specificity of peak plasma
HHV-6 viral loads for HHV-6-PALE in our cohort
(Figure 2). Among all tested patients, a plasma
HHV-6 viral load $105 copies/mL was 71% sensitive
and 94% specific for a diagnosis of HHV-6-PALE.
Specificity increased to 98% for viral loads $106 cop-
ies/mL. Among tested patients who underwent
UCBT, a plasma HHV-6 viral load $105 copies/mL
was 80% sensitive and 86% specific for a diagnosis of
HHV-6-PALE. Specificity increased to 97% for viral
loads$106 copies/mL. Adult-donor HSCT recipients
had slightly lower sensitivities and higher specificities
at these viral load thresholds.Treatment and Outcomes
Intravenous foscarnet at a dose of 180 mg/kg/day
was used off-label to treat 18 of 19 patients. All patients
with high clinical suspicion for HHV-6-PALE or de-
tection of HHV-6 DNA in CSF specimens were
Figure 1. This figure demonstrates brain axial fluid attenuation inversion recovery (FLAIR) magnetic resonance images (MRIs) from 2 patients with
human herpesvirus-6 posttransplantation acute limbic encephalitis. (A) MRI from the recipient of an adult-donor hematopoietic stem cell transplantation
showing characteristic well-demarcated, high-intensity signal abnormalities in the bilateral medial temporal lobes involving the hippocampus and amyg-
dala. (B) MRI from the recipient of an umbilical cord blood transplantation showing signal abnormalities extending beyond the limbic system.
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ture was obtained before or within 24 hours of initia-
tion of definitive treatment in all patients. Treatment
was only continued for patients with detectable
HHV-6 DNA in the CSF. Some early patients in the
cohort were initially started on acyclovir or ganciclo-
vir. Time to treatment after HHV-6-PALE symptom
onset was a median of 6 days (range, 1-13 days) in pa-
tients who underwent UCBT and continued for a me-
dian of 16 days (range, 7-28 days). Time to treatment
was a median of 3 days (range, 1-13 days) in adult-
donor recipients and continued for a median of 21
days (range, 7-42 days). One patient did not receive an-
tiviral treatment as this was not consistent with her
goals of care at the time the diagnosis was made.
Most patients showed mild to moderate improve-
ment in their symptoms shortly after the initiation of
foscarnet therapy, but 9 of 13 patients surviving long
enough to demonstrate recovery were left with resid-
ual fatigue and episodic memory impairment. Al-
though no adult-donor recipients died as a direct
result of their encephalitis, 50% of the patients who
underwent UCBT died a median of 45 days (range,
35-74 days) after transplantation and 18 days (range,
7-26 days) after symptom onset due to complications
directly attributable to HHV-6-PALE. Deaths oc-
curred after similar courses punctuated by progressive
encephalopathy and unresponsiveness requiring me-
chanical ventilation without return of consciousness.
Of the 5 patients who died, 4 of the patients never en-
grafted, and 2 of these patients underwent subsequent
UCBT due to failure of the initial UCBT. There were
no clear associations between morbidity and mortality
and time to treatment; plasma or CNS HHV-6 viral
loads; or other clinical, laboratory, or radiographic
findings.DISCUSSION
UCBT is frequently used in patients who have no
suitable or readily available matched or related stem
cell donor. However, UCBT is often associated with
slower engraftment and impaired immune reconstitu-
tion relative to adult-donor HSCT, resulting in an in-
creased risk for infectious complications. Moreover,
there is no passively transferred immunity to bridge
the period from conditioning to immunologic recov-
ery. One of the most severe infections in the early pe-
riod after transplantation is HHV-6-PALE, which
engenders mortality or serious morbidity in the major-
ity of affected patients.
In this study of a large cohort of HSCT recipients,
the most significant and stable predictors of HHV-6-
PALE were UCBT, time-dependent aGVHD grades
II to IV, and adult-mismatched donor. The overall cu-
mulative incidence of this syndrome was 1.4% with an
IR of 0.15 of 1000 patient-days. HHV-6-PALE oc-
curred much more frequently after UCBT (9.9%)
than after adult-donor HSCT (0.7%), and there was
a 25% risk for HHV-6-PALE after a second UCBT.
Mortality due to progressive HHV-6-PALE was
50% in UCBT recipients compared with no mortality
after adult-donor HSCT.
Although it is possible that we did not identify all
patients with HHV-6 reactivation in the CNS, any
symptomatic patient with a likely diagnosis of HHV-
6-PALE during this study period underwent CSF anal-
ysis before or within 24 hours of antiviral treatment for
HHV-6. We think our definition for HHV-6-PALE
captured only true cases of infection in this cohort.
All patients diagnosed withHHV-6-PALE had detect-
able HHV-6 DNA in the CSF using a quantitative
PCR assay in addition to typical symptoms of limbic
Figure 2. Receiver-operating characteristic (ROC) curves plotting the sensitivity and specificity of peak plasma human herpesvirus-6 (HHV-6) viral
loads for the development of posttransplantation acute limbic encephalitis (HHV-6-PALE). (A) Two hundred ten patients in the entire cohort had plasma
HHV-6 testing, and 92 were positive. (B) Sixty-eight patients in the umbilical cord blood transplantation (UCBT) cohort had plasma HHV-6 testing, and
49 were positive.
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showed objective signs of medial temporal lobe abnor-
malities affecting limbic structures. Although 5 pa-
tients did not have MRI evidence of limbic
encephalitis, this is consistent with the findings of a re-
view of 48 HHV-6-PALE cases in which approxi-
mately 30% of imaged patients had normal brain
MRIs [9].Normal imagingmay bemore common early
in the disease course. Repeat scanning, if obtained,may
show interval development of disease, as seen in 2 pa-
tients from this study. Furthermore, the finding of
HHV-6 DNA in CSF samples was unlikely to be inci-
dental, as this is rarely demonstrated in CSF samples
from posttransplantation patients undergoing lumbar
puncture for neurologic symptoms due to diagnoses
other than acute limbic encephalitis [19,37].
Preemptive treatment of CMV DNAemia with
ganciclovir or foscarnet could have lowered the risk
for HHV-6-PALE by inadvertently treating HHV-6;
however, there was no difference in the cumulative in-
cidence of HHV-6-PALE among CMV seropositive
recipients compared to CMV seronegative recipients.
In addition, the median time to development of
HHV-6 viremia after HSCT occurred earlier than
the typical time to CMV viremia [38,39], making
preemptive antiviral treatment of CMV DNAemia
unlikely to impact the risk for HHV-6-PALE.
Detection of HHV-6 DNA in clinical specimens
does not always indicate active infection and requires
careful interpretation, as recent research demonstrates
that this virus may be chromosomally integrated in nu-
cleated cells of up to 2% of the population [40-43].
Individuals with ciHHV-6 can have persistently ele-
vated viral loads in blood and CSF specimens thatare typically .105.5 copies/mL. Transplantation
recipients with HHV-6 reactivation have transiently
detectable HHV-6 DNA usually\105 copies/mL in
blood samples, although higher viral loads have been
reported. Seven patients diagnosed with HHV-
6-PALE in this study had plasma viral loads .105.5
copies/mL that could be suggestive of ciHHV-6; 4
had objective radiographic abnormalities consistent
with limbic encephalitis, 2 had nonspecific brain
MRIs, and 1 did not have brain imaging. Of the 3 pa-
tients without objective evidence of limbic disease, all
had subsequent testing documenting decreases in
HHV-6 plasma viral loads to\1000 copies/mL. In ad-
dition, CSF samples from 6 of 7 patients with plasma
HHV-6 viral loads .105.5 copies/mL had\5 nucle-
ated cells, indicating that virus identification was un-
likely due to ciHHV-6 detected in inflammatory
cells. Thus, we think that all patients diagnosed with
HHV-6-PALE had active HHV-6 infections.
A recent study exploring HHV-6-associated CNS
disease after UCBT suggested a higher incidence than
seen in our cohort. Mori et al. [21] reported a 15.7%
cumulative incidence rate of HHV-6-PALE or myeli-
tis after UCBT, 2.8% after adult-donor HSCT, and
28.6% after 2 or more UCBTs at their institution.
Similar to our findings, logistic regression analysis of
their data identified UCBT and UCBT re-
transplantation as risk factors for HHV-6-PALE.
The higher rate of HHV-6-associated CNS disease
in their study was likely due to a less-stringent case def-
inition.
The increased incidence and morbidity of HHV-
6-PALE in patients undergoingUCBT is likely related
to the higher frequency and degree of HHV-6
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to UCBT that may account for this include the im-
plicit use of mismatched and URD cells, absence of
primed HHV-6-specific T cells in the immature allo-
graft, frequent treatment with T cell depleting agents,
and prolonged neutropenia, especially in patients who
fail to engraft and require a second transplantation [8-
10,23]. Among tested patients who underwent UCBT,
72% had detectable plasma HHV-6 DNA at greater
levels compared with 30% of tested adult-donor recip-
ients within 100 days of transplantation. We found
that patients with higher viral loads were at increased
risk for HHV-6-PALE. Plasma HHV-6 viral loads
$105 copies/mL were 94% specific for a diagnosis of
HHV-6-PALE among all tested patients undergoing
allogeneic HSCT and 86% specific after UCBT; spec-
ificities were 98% and 97%, respectively, for viral
loads $106 copies/mL. These values should be inter-
preted with caution, as plasma HHV-6 viral load test-
ing was clinically driven when the treating clinician
had concern for HHV-6 reactivation. However, data
reported by Ogata et al. [44] in a study of 111 patients
who had weekly PCR surveillance for plasma HHV-6
DNA demonstrated similar sensitivities and specific-
ities for these viral load thresholds.
Inflammatory conditions such as aGVHD grade II
to IV and its treatment have also been associated with
HHV-6-PALE [44]. Indeed, time-dependent aGVHD
grade II to IV was significantly associated with HHV-
6-PALE in our study. Although this association was
driven by the adult-donor cohort and did not reach sta-
tistical significance among UCBT recipients alone,
this was likely a result of a small number of events
due to the lower rate of aGVHD after UCBT [45].
The incidence of aGVHD grade II to IV was relatively
low in this cohort, likely attributable to the use of
sirolimus-containing GVHD prophylaxis [32]. Given
our findings, one might expect an increased incidence
of HHV-6-PALE in a patient population with a higher
rate of aGVHD. Patients with significant aGVHD be-
fore HHV-6-PALE onset were treated with systemic
glucocorticoids, so it is difficult to discern the contri-
bution of each element separately in regard to the asso-
ciation with HHV-6-PALE.
Treatments that deplete T-lymphocytes, which
probably play an important role in immune control
of HHV-6 replication, may increase the risk for
HHV-6 reactivation. Studies have demonstrated that
treatment with steroids [9,23], ATG [11], and anti-
CD3 antibodies (such as BC3 [26] and OKT3 [46])
increase the risk for HHV-6 viremia.We had high sus-
picion that ATG use would increase the risk of HHV-
6-PALE, especially given that patients who underwent
UCBTwere more likely to receive ATG in our cohort.
However, ATG was not associated with HHV-6-
PALE on adjusted Cox modeling. Perhaps increased
risk from ATG was mitigated by its protective effectfor aGVHD. RIC protocols that do not include
ATG will be instructive in further evaluating its asso-
ciation with HHV-6-PALE after UCBT.
Patient-donor HLA mismatch is an additional
cause of prolonged immune dysfunction after HSCT
and has been associated with HHV-6 reactivation
[8,23,47]. Unsurprisingly, patient-donor mismatch
was associated with HHV-6-PALE in our adult-
donor recipients.
Some clinical features of HHV-6-PALE after
UCBT deserve mention. Three UCB recipients devel-
oped visual hallucinations, and 1 patient had extensive
extralimbic findings on MRI and autopsy studies. In-
terestingly, visual hallucinations and extralimbic dis-
ease are more commonly described in pediatric cases
of HHV-6-PALE [48-50]. The reasons for these
similarities are unclear. HHV-6-PALE symptom on-
set occurred before engraftment in 7 of 10 patients
who underwent UCBT compared to 1 of 9 adult-
donor recipients. Symptoms also began later after
UCBT, despite similar timing of blood HHV-6 reac-
tivation [8]. These findings may be due to a lack of
or delayed engraftment and impaired immune control
that is common after UCBT. They also suggest that
HHV-6B has important neuropathic effects indepen-
dent of immune system activation, as 4 patients died
from this syndrome without ever engrafting.
Early treatment for HHV-6-PALE after HSCT,
as well as prophylactic or Preemptive measures, may
improve outcomes and reduce the incidence of this dis-
ease. Foscarnet, cidofovir, and ganciclovir are available
antiviral agents that demonstrate in vitro and in vivo
activity against HHV-6, but there have been no con-
trolled trials to study these agents for HHV-6 therapy
[2,25,51,52]. A few studies evaluating the efficacy of
preemptive or prophylactic ganciclovir or foscarnet
to prevent HHV-6-PALE have been disappointing,
perhaps due to the dynamic kinetics ofHHV-6 viremia
[17,53,54]. However, based on the results of this and
other studies onHHV-6 inHSCT, it would be reason-
able to performweeklyHHV-6 surveillance in patients
undergoing UCBT or mismatched adult-donor
HSCT, as well as those who develop aGVHD grades
II to IV or other conditions requiring treatment with
T lymphocyte–depleting agents. Given the available
data, we recommend a low threshold for starting treat-
ment in patients with plasma HHV-6 viral loads$106
copies/mL or patients with viral loads $105 copies/
mL in addition to findings concerning CNS disease.
Lumbar puncture should be performed as soon as it
can be safely done and ideally before antiviral treat-
ment. Treatment should be continued for 3 to 4 weeks
only if HHV-6 DNA is detected in the CSF by PCR.
Prospective screening for HHV-6 in high-risk pa-
tients, as well as follow-up HHV-6 testing, will be im-
portant to evaluate for ciHHV-6 and response to
treatment. We favor the use of foscarnet at a dose of
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in this patient population due to bone marrow sup-
pression [55], lower in vitro efficacy [56], and concern
for HHV-6 resistance [57-59]. Additional randomized
controlled studies evaluating the efficacy of
prophylactic or preemptive treatment of patients
with plasma HHV-6 viremia will be important to fur-
ther refining management of these patients.
In summary, we defined the incidence of HHV-
6-PALE in patients receiving an UCBT at our institu-
tion and identified UCBT, time-dependent aGVHD
grades II to IV, and adult-mismatched donor as risk
factors for this syndrome. Detailed review of patient
medical records highlighted the increased morbidity
and mortality of HHV-6-PALE after UCBT com-
pared to adult-donor HSCT. Strategies to minimize
the impact of HHV-6-PALE in this population need
to be further evaluated.
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